Context Therapeutics Inc (CNTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.37 (-3.99%), Market cap $0.20B, 52-week low–high $0.55 ~ $3.36.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Context Therapeutics Inc are updated in real time on BlackAll Trade.
Context Therapeutics Inc trades at $0.37 (-3.99%). Real-time quotes and charts are available on BlackAll Trade.
Context Therapeutics Inc has a market cap of about $0.20B.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3